Analyze Diet

Cerebrospinal fluid and serum concentrations of ponazuril in horses.

Abstract: Ponazuril was administered orally to 10 adult horses at 5 mg/kg body weight, once a day for 28 days. Blood was collected once a week from each horse from Days 0 through 35, daily from Days 35 through 42, and on Day 49. Cerebrospinal fluid (CSF) was also collected once a week from Day 0 through Day 49. Concentrations of ponazuril in the serum and CSF were determined, and pharmacokinetic calculations were performed. Ponazuril was readily absorbed following oral administration; and after 7 days of dosing, the serum concentration was 4.33 +/- 1.10 mg/L, and the mean CSF concentration was 0.162 +/- 0.05 mg/L. Cerebrospinal fluid concentration did not vary during the 28 days of dosing and concentrations declined rapidly after cessation of administration on Day 28. The terminal elimination half-life ofponazuril in serum (using Day 28 to 42 results) was 4.3 +/- 0.6 days. Repeated CSF collections from the atlanto-occipital space did not induce changes in the immunoglobulin G index or albumin quotient. It was concluded that oral administration of ponazuril to healthy horses at 5 mg/kg provided concentrations of ponazuril in the CSF that are presumed to be adequate for the treatment of equine protozoal myeloencephalitis (EPM). These results indicate that this dosage rate should be investigated for efficacy against EPM.
Publication Date: 2001-07-01 PubMed ID: 19746666
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study administered Ponazuril, a drug commonly used to treat horses for protozoal infections, to 10 adult horses once daily for 28 days, and measured the concentrations of the drug in the blood and cerebrospinal fluid over time to determine its absorption and elimination rates. It found that the drug was adequately absorbed and suggested it could be effective in treating equine protozoal myeloencephalitis (EPM).

Introduction

  • This research was conducted to understand the pharmacokinetics of the drug Ponazuril in horses, including absorption, distribution, and elimination, by monitoring its concentration in blood serum and cerebrospinal fluid (CSF).
  • The ultimate goal of the study was to assess whether the oral administration of Ponazuril could potentially be used to treat equine protozoal myeloencephalitis (EPM), a common neurological disease in horses caused by protozoan parasites.
  • Methodology

  • Each horse in the study was administered Ponazuril orally, once a day for 28 days at a dose rate of 5mg/kg body weight.
  • Blood samples were taken weekly from each horse from Day 0 to Day 35, daily from Days 35 to 42, and once on Day 49. CSF samples were also collected weekly from Day 0 to Day 49.
  • Ponazuril concentrations in both the blood serum and CSF samples were then determined to understand the absorption and distribution of the drug in the body.
  • Results

  • The results showed that Ponazuril was readily absorbed after oral administration. After a week of dosing, the average serum concentration of the drug was 4.33 +/- 1.10 mg/L, and the average CSF concentration was 0.162 +/- 0.05 mg/L.
  • The CSF concentration of the drug did not vary during the dosing period, and concentrations declined rapidly after the cessation of administration on Day 28.
  • The terminal elimination half-life of Ponazuril in the serum, calculated using the results from Day 28 to Day 42, was 4.3 +/- 0.6 days.
  • Importantly, repeated CSF collections did not induce changes in the immunoglobulin G index or albumin quotient, key indicators of the horse’s immune response due to CSF extractions.
  • Conclusion

  • The study concluded that oral administration of Ponazuril at a dose rate of 5 mg/kg in healthy horses resulted in concentrations of the drug in the CSF that are presumed to be well-suited for treating EPM.
  • The results suggest that this dosage rate and administration method should be investigated in further studies for potential efficiency against EPM.
  • Cite This Article

    APA
    Furr M, Kennedy T. (2001). Cerebrospinal fluid and serum concentrations of ponazuril in horses. Vet Ther, 2(3), 232-237.

    Publication

    ISSN: 1528-3593
    NlmUniqueID: 100936368
    Country: United States
    Language: English
    Volume: 2
    Issue: 3
    Pages: 232-237

    Researcher Affiliations

    Furr, M
    • Virginia-Maryland Regional College of Veterinary Medicine, Marion duPont Scott Equine Medical Center, PO Box 1938, Leesburg, VA 20177, USA.
    Kennedy, T

      MeSH Terms

      • Animals
      • Antiprotozoal Agents / blood
      • Antiprotozoal Agents / cerebrospinal fluid
      • Drug Administration Schedule
      • Horses / cerebrospinal fluid
      • Male
      • Triazines / blood
      • Triazines / cerebrospinal fluid

      Citations

      This article has been cited 5 times.
      1. Jacobson ER, Stacy NI, Mader DR, Moretti R, Zirkelbach B, Carlile O, O'Connor CD, Caperton KJ, Maxwell LK. Pharmacokinetics of ponazuril after administration of a single oral dose to green turtles (Chelonia mydas).. Vet Q 2021 Dec;41(1):323-331.
        doi: 10.1080/01652176.2021.2008045pubmed: 34789079google scholar: lookup
      2. Furr M, Kennedy T. Effects of coadministration of corn oil and ponazuril on serum and cerebrospinal fluid concentrations of ponazuril in horses.. J Vet Intern Med 2020 May;34(3):1321-1324.
        doi: 10.1111/jvim.15765pubmed: 32301131google scholar: lookup
      3. Reed SM, Furr M, Howe DK, Johnson AL, MacKay RJ, Morrow JK, Pusterla N, Witonsky S. Equine Protozoal Myeloencephalitis: An Updated Consensus Statement with a Focus on Parasite Biology, Diagnosis, Treatment, and Prevention.. J Vet Intern Med 2016 Mar-Apr;30(2):491-502.
        doi: 10.1111/jvim.13834pubmed: 26857902google scholar: lookup
      4. Dubey JP, Howe DK, Furr M, Saville WJ, Marsh AE, Reed SM, Grigg ME. An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM).. Vet Parasitol 2015 Apr 15;209(1-2):1-42.
        doi: 10.1016/j.vetpar.2015.01.026pubmed: 25737052google scholar: lookup
      5. Kritzner S, Sager H, Blum J, Krebber R, Greif G, Gottstein B. An explorative study to assess the efficacy of toltrazuril-sulfone (ponazuril) in calves experimentally infected with Neospora caninum.. Ann Clin Microbiol Antimicrob 2002 Oct 18;1:4.
        doi: 10.1186/1476-0711-1-4pubmed: 12437777google scholar: lookup